Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | REGN7075 |
| Synonyms | |
| Therapy Description |
REGN7075 is a bispecific antibody targeting EGFR and CD28, which may trigger cytotoxic T-lymphocytes-mediated immune response against EGFR-expressing tumor cells (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| REGN7075 | REGN-7075|REGN 7075 | CD28 Antibody 12 EGFR Antibody 73 | REGN7075 is a bispecific antibody targeting EGFR and CD28, which may trigger cytotoxic T-lymphocytes-mediated immune response against EGFR-expressing tumor cells (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06465329 | Phase II | Cemiplimab + REGN7075 REGN7075 Cemiplimab | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | TUR | FRA | ESP | DEU | BRA | 0 |